<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Journal of Medical and Surgical Research</JournalTitle>
      <Volume-Issue>Special Issue "Pathology"</Volume-Issue>
      <Season>March, 2023</Season>
      <ArticleType>JMSR Pathology</ArticleType>
      <ArticleTitle>The clinicopathological features and prognostic impact of her2-low breast tumors subtype. New opportunity for untreated patients.</ArticleTitle>
          <FirstName>Layla Tahiri</FirstName>
          <FirstName>Hinde El</FirstName>
      <Abstract>Introduction: The emergence of a new tumor entity called HER2-low breast cancer leads us to reconsider therapeutic indications in patients whose tumors were considered as HER2-negative. HER2-Low subtype was defined as HER2 1+ and HER2 2+ FISH not amplified. The development of antibody-drug conjugates (ADCs) allows using HER2 as a vector of a cytotoxic drug with significant clinical efficacy and less side effects in breast cancer with HER2 low expression. Herein, we aimed to evaluate the differences in clinicopathological characteristics and prognostic factors between HER2-Low breast carcinoma and those with HER2-negative cancer, according to HR profile.&#13;
Methods: We conducted a 10-years bicentric cohort study on 1955 invasive breast tumors of Moroccan patients, collected at two Moroccan centers between 2012 and 2022.&#13;
Results: Out of 1955 BC patients, 49,3% were classified as HER2-Low; of which 80,7%&#13;
were hormone receptors positive. The clinicopathological features indicate that HER2-Low subtype behave much more like HER2-positive than HER2-negative tumors. The survival analysis showed that the HER2-Low subtype-belonging patients present significantly the poorest prognosis in disease free survival (p=0,003). Hormonal dependent tumors show a significant difference according to HER2 subtypes in DFS (p</Abstract>
      <Keywords>HER2 low, breast cancer, hormone receptors, survival</Keywords>
        <Abstract>https://journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=14389&amp;title=The clinicopathological features and prognostic impact of her2-low breast tumors subtype. New opportunity for untreated patients.</Abstract>
        <References>Marchiand;ograve; C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021 Jul;72:123-135. doi: 10.1016/j.semcancer.2020.02.016.&#13;
	Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C, de Azambuja E. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel). 2021 Jun 5;13(11):2824. doi: 10.3390/cancers13112824.&#13;
	Schettini F, Chic N, Brasand;oacute;-Maristany F, Parand;eacute; L, Pascual T, Conte B, Martand;iacute;nez-Sand;aacute;ez O, Adamo B, Vidal M, Barnadas E, Fernand;aacute;ndez-Martinez A, Gonzand;aacute;lez-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gaviland;aacute; J, Barrios CH, Lluch A, Martand;iacute;n M, Locci M, De Placido S, Prat A. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2.&#13;
	Zhang H, Peng Y. Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer. Cancers (Basel). 2022 Dec 25;15(1):126. doi: 10.3390/cancers15010126.</References>